Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL2248963

N.Nc1cnc2ccc(Br)cc2c1-c1ccccc1Cl

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.56
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.47
PTGES O14684 3/20 0.44
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
TNF P01375 1/20 0.40
THRB P10828 1/20 0.38
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRA6 Q16445 1/20 0.37
DPP4 P27487 1/20 0.37
PDE2A O00408 1/20 0.37
PDE10A Q9Y233 1/20 0.37
BACE1 P56817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL2248185 0.86 NR4A2 (0.46) SMN1; SMN2KMT2AMAPTGABRA1GABRG2
SCHEMBL8835043 0.85 NR4A2 (0.47) SMN1; SMN2KMT2AMAPTGABRA1GABRG2
Ammonia Solution, Strong SCHEMBL2248291 0.84 PTGES (0.44) SMN1; SMN2GAAKMT2APTGESMAPT
Ammonia Solution, Strong SCHEMBL4775543 0.84 GRM2 (0.41) SMN1; SMN2GAAMAPTTNFBACE1
SCHEMBL28038009 0.82 PTGES (0.45) SMN1; SMN2GAAKMT2APTGESHTT
SCHEMBL8835094 0.82 GRM2 (0.41) SMN1; SMN2GAAMAPTTNFBACE1
SCHEMBL9162855 0.82 HTR5A (0.41) SMN1; SMN2
SCHEMBL9159755 0.81 NCF1 (0.42) KMT2AMAPTDPP4
Ammonia Solution, Strong SCHEMBL2247533 0.81 MAPT (0.40) SMN1; SMN2KMT2APTGESMAPTDPP4
SCHEMBL8835425 0.79 MAPT (0.40) SMN1; SMN2KMT2APTGESMAPTDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998972-B2 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2011-08-16 US disclosed
EP-1509521-B1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2008-08-20 EP disclosed
US-20050245562-A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2005-11-03 US disclosed
EP-1509521-A2 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2005-03-02 EP disclosed
WO-2003097641-A2 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245562-A1 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases ABL1, PRKCA, PRKCQ SMN1; SMN2 1157/4885GAA 1024/4885KMT2A 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.